This Phase II randomized, double-blind, placebo-controlled trial assessed the safety and efficacy of intravenous allogeneic human mesenchymal stem cells (allo-hMSCs) in 30 elderly patients (mean age 75.5 years) with aging frailty. Participants received either 100 million or 200 million allo-hMSCs or placebo. No treatment-related serious adverse events were observed. The
